<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1149">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04390412</url>
  </required_header>
  <id_info>
    <org_study_id>23568</org_study_id>
    <secondary_id>IRCT20200509047366N1</secondary_id>
    <nct_id>NCT04390412</nct_id>
  </id_info>
  <brief_title>Low Dose Radiotherapy in COVID-19 Pneumonia</brief_title>
  <official_title>Assessment of Adding Low Dose Pulmonary Radiotherapy to the National Protocol of COVID-19 Management: A Pilot Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shahid Beheshti University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shahid Beheshti University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Moderate to severe cases of SARS-associated ARDS based on inclusion/ exclusion criteria and
      the decision made in multi- disciplinary team are treated with 0.5 Gy whole lung radiation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SARS-associated ARDS (acute respiratory distress syndrome) is the most fatal outcome of
      COVID-19 systemic infection. To overcome the uncontrolled inflammation leading to ARDS and
      respiratory failure, several drugs have been investigated in this situation with the most
      promising results coming from anti-inflammatory agents that directly or indirectly inhibit
      IL-6 and its counterparts of inflammation.

      Low dose radiation, as opposed to high dose, has documented anti-inflammatory effects that
      are exercised through various mechanisms including decrease in pro-inflammatory cytokines
      such as IL-6.

      In this pilot clinical trial, the patients are carefully selected according to inclusion
      /exclusion criteria and the clinical judgement of the multi- disciplinary team.Their
      diagnostic CT scan will be used to plan an AP/ PA radiotherapy treatment to both lungs and
      the set-up positioning information is obtained from anatomical landmarks. The patient will be
      referred for a fraction of 0.5 Gy to both lungs and for the next 28 days the clinical
      para-clinical and radiologic variables of disease severity will be monitored closely. Should
      the patient's clinical course indicate and the multi- disciplinary team approves, they may be
      subjected to another fraction of 0.5 Gy to a maximum of 1 Gy in two fractions at least 72
      hours apart. All the patients will also receive the standard national protocol of COVID-19
      management.

      A total of 5 patients will be enrolled in the RT arm, providing favourable results seen in
      the first set of patients, the team will decide on recruiting a larger number for a phase II
      clinical trial.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 4, 2020</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline blood oxygenation</measure>
    <time_frame>28 days</time_frame>
    <description>O2 saturation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Hospital stay days</measure>
    <time_frame>28 days</time_frame>
    <description>Total days the patient is admitted to hospital</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of ICU stay days</measure>
    <time_frame>28 days</time_frame>
    <description>Total days the patient is admitted to ICU</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of intubation events</measure>
    <time_frame>28 days</time_frame>
    <description>Total number of intubations performed after the treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>WBC</measure>
    <time_frame>28 days</time_frame>
    <description>Changes in WBC count if base-line is abnormal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelets</measure>
    <time_frame>28 days</time_frame>
    <description>Changes in Platelets count if base-line is abnormal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CRP</measure>
    <time_frame>Day 1</time_frame>
    <description>Changes in CRP serum level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CRP</measure>
    <time_frame>Day 2</time_frame>
    <description>Changes in CRP serum level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CRP</measure>
    <time_frame>Day 3</time_frame>
    <description>Changes in CRP serum level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CRP</measure>
    <time_frame>Day 4</time_frame>
    <description>Changes in CRP serum level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CRP</measure>
    <time_frame>Day 5</time_frame>
    <description>Changes in CRP serum level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IL-6</measure>
    <time_frame>Day 1</time_frame>
    <description>Changes in IL-6 serum level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IL-6</measure>
    <time_frame>Day 2</time_frame>
    <description>Changes in IL-6 serum level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IL-6</measure>
    <time_frame>Day 3</time_frame>
    <description>Changes in IL-6 serum level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IL-6</measure>
    <time_frame>Day 4</time_frame>
    <description>Changes in IL-6 serum level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IL-6</measure>
    <time_frame>Day 5</time_frame>
    <description>Changes in IL-6 serum level</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>COVID</condition>
  <condition>SARS (Severe Acute Respiratory Syndrome)</condition>
  <arm_group>
    <arm_group_label>Low Dose Radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5 Gy radiation to both lungs in an AP/PA fashion</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Low Dose Radiotherapy</intervention_name>
    <description>0.5 Gy radiation to both lungs in an AP/PA treatment plan</description>
    <arm_group_label>Low Dose Radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed COVID-19 diagnosis ( PCR or serologic or radiographic)

          -  Presence of pulmonary involvement ( defined by P/F ratio or NIV need)

          -  Less than 3 days since the onset of ARDS

          -  Age &gt; 60 years

          -  ↑ IL-6 ( if available)

          -  ↑ CRP

        Exclusion Criteria:

          -  Lack of informed consent

          -  Inability to transfer to the radiation unit

          -  Hemodynamic instability

          -  Septic shock and organ dysfunction

          -  Severe ARDS P/F ratio ≤ 100 mmHg

          -  History of cardiac failure

          -  Contraindications to radiation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmad Ameri, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nazanin Rahnama, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Imam Hossein Hospital</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <reference>
    <citation>Calabrese EJ, Dhawan G. How radiotherapy was historically used to treat pneumonia: could it be useful today? Yale J Biol Med. 2013 Dec 13;86(4):555-70.</citation>
    <PMID>24348219</PMID>
  </reference>
  <reference>
    <citation>Large M, Hehlgans S, Reichert S, Gaipl US, Fournier C, Rödel C, Weiss C, Rödel F. Study of the anti-inflammatory effects of low-dose radiation: The contribution of biphasic regulation of the antioxidative system in endothelial cells. Strahlenther Onkol. 2015 Sep;191(9):742-9. doi: 10.1007/s00066-015-0848-9. Epub 2015 Jun 8.</citation>
    <PMID>26051282</PMID>
  </reference>
  <reference>
    <citation>Clayton B. Hess, MD, MPH, and Mohammad K. Khan, MD, PhD, &quot;Low dose chest radiation for COVID-19 patients&quot; Winship Emory News post, April 27, 2020</citation>
  </reference>
  <reference>
    <citation>Kirkby C, Mackenzie M. Is low dose radiation therapy a potential treatment for COVID-19 pneumonia? Radiother Oncol. 2020 Jun;147:221. doi: 10.1016/j.radonc.2020.04.004. Epub 2020 Apr 6.</citation>
    <PMID>32342871</PMID>
  </reference>
  <reference>
    <citation>Kefayat A, Ghahremani F. Low dose radiation therapy for COVID-19 pneumonia: A double-edged sword. Radiother Oncol. 2020 Jun;147:224-225. doi: 10.1016/j.radonc.2020.04.026. Epub 2020 Apr 20.</citation>
    <PMID>32342874</PMID>
  </reference>
  <reference>
    <citation>Stefano M Magrini, Prof et al. COVID-19 Pneumonitis Low Dose Lung Radiotherapy (COLOR-19). ClinicalTrials.gov Identifier: NCT04377477</citation>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 13, 2020</study_first_submitted>
  <study_first_submitted_qc>May 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2020</study_first_posted>
  <last_update_submitted>July 9, 2020</last_update_submitted>
  <last_update_submitted_qc>July 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Low Dose Lung Radiotherapy</keyword>
  <keyword>COVID-19</keyword>
  <keyword>anti-inflammatory</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
    <mesh_term>Coronavirus Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD will be shared after the completion of study to other researchers.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>After the completion of trial for one year.</ipd_time_frame>
    <ipd_access_criteria>Verified researchers</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

